Posts

Opinion: Surfing, camping, and deciding when to stop: A...

“We let people dialyze to live, rather than living to dialyze,” says John Agar i...

STAT+: NYU launched private ChatGPT for its health data...

Use of generative AI in health care is still new but NYU Langone is embracing br...

Opinion: Current large language models will not fix hea...

Today, AI in health care is splintered at best. There’s a better way.

What a review of gender-affirming care research by a to...

The AAP and other experts say the systematic review indicates their confidence i...

Listen: Vivek’s star turn, leaky drug data, & biotech a...

Does biotech prepare you for the presidency? Who really wants to gut the FDA? An...

Regeneron receives FDA approval for longer-lasting visi...

The recent approvals signal a swifter turnaround for Regeneron than what analyst...

FDA greenlights Pfizer’s RSV vaccine for administration...

In a significant stride toward safeguarding the health of newborns, the Food and...

Spanish pharmaceutical company Serra Pamies faces EMA p...

The Serra Pamies facility located in Reus, Spain, has had its manufacturing oper...

Pfizer Slashes Enrollment For Lyme Disease Trial Follow...

Due to issues that arose with the CRO responsible for developing Pfizer’s Lyme d...

Japan grants patent for BioArctic’s Parkinson’s disease...

Japan has granted a new drug substance patent for BioArctic’s monoclonal antibod...

Dizal receives approval in China for NSCLC therapy

Dizal has received approval from China’s NMPA for sunvozertinib to treat adult p...

CVS Health enters biosimilar fray with launch of new su...

The newly-launched business, called Corvardis, is already targeting the Humira b...

US Elections: Vivek Ramaswamy makes brazen debate debut

Candidates at the first Republican primary debate diverged on the extent of abor...

Novaliq pursues EMA approval for dry eye disease drug

The EMA accepted Novaliq’s marketing authorisation application for cyclosporine ...

SK Bioscience and Vaxxas partner to develop needle-free...

The companies received a $3.67m grant to develop a low-cost, temperature-stable ...

Diabetic macular oedema market expected to reach $9.6bn...

The diabetic macular oedema (DMO) market is expected to grow at a 6.0% CAGR over...